Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0)

R. Stasi, G. Del Poeta, A. Venditti, M. Masi, E. Stipa, T. Dentamaro, C. Cox, B. Dallapiccola, G. Papa

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Reports of treatment of patients with minimally differentiated acute myeloid leukemia (AML-M0) are limited, heterogeneous, and controversial. We verified the prognosis of this subtype by analyzing the results of 189 consecutive patients with de novo AML. Fifteen cases fitting the criteria of AML-M0 were identified. No clinical features distinguished them from other patients with AML. The median age was 61 years (range 27 to 70), with a leukocyte count ranging from 0.6 to 185 x 109/L. In all cases the leukemic cells expressed CD34 and reacted with at least one of the antibodies to early myeloid antigens, ie, CD13, CD33, or myeloperoxidase. Immunophenotypic analysis also showed positivity for CD7 in seven samples and the multidrug- resistance P-glycoprotein (P-170) in six. Cytogenetic analysis was abnormal in 12 of the 13 patients in whom an adequate number of mitoses could be evaluated. No single abnormality prevailed, the most common findings being trisomy 8 (three cases) and aberrations of chromosome 7 (two cases). Antileukemic treatment differed according to age, but for remission induction, all patients received a combination of cytosine arabinoside and an anthracycline or mitoxantrone. The prognosis of patients with AML-M0 was remarkably poor as compared with the other French-American-British subtypes. Whereas the overall rate of complete remission (CR) was 58% with a median survival of 63 weeks, only 6 of the 15 patients with AML-M0 achieved a CR, and the median survival of this group was 16 weeks (range 3 to 39). The major determinant of treatment failure was unresponsiveness to chemotherapy, as only one patient died of infection during the hypoplastic phase. The CR duration of responders was short, ranging from 3 to 22 weeks, and no second remissions were observed. We conclude that conventional combination chemotherapy yields disappointing results in AML-M0. The reason for this may be the convergence of various unfavorable prognostic factors, such as (1) the high incidence of cytogenetic abnormalities; (2) the lack of differentiation features and the expression of immaturity markers such as CD34 and CD7; and (3) the frequent expression of P-170. Nonconventional therapeutic approaches should be developed to alter the prognosis of this form of leukemia.

Original languageEnglish
Pages (from-to)1619-1625
Number of pages7
JournalBlood
Volume83
Issue number6
Publication statusPublished - 1994

Fingerprint

Chemotherapy
Treatment Failure
Acute Myeloid Leukemia
Mitoxantrone
Anthracyclines
Cytarabine
P-Glycoprotein
Chromosomes
Aberrations
Peroxidase
Antigens
Antibodies
CD13 Antigens
Remission Induction
Chromosomes, Human, Pair 7
Survival
Cytogenetic Analysis
Multiple Drug Resistance
Combination Drug Therapy
Leukocyte Count

ASJC Scopus subject areas

  • Hematology

Cite this

Stasi, R., Del Poeta, G., Venditti, A., Masi, M., Stipa, E., Dentamaro, T., ... Papa, G. (1994). Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). Blood, 83(6), 1619-1625.

Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). / Stasi, R.; Del Poeta, G.; Venditti, A.; Masi, M.; Stipa, E.; Dentamaro, T.; Cox, C.; Dallapiccola, B.; Papa, G.

In: Blood, Vol. 83, No. 6, 1994, p. 1619-1625.

Research output: Contribution to journalArticle

Stasi, R, Del Poeta, G, Venditti, A, Masi, M, Stipa, E, Dentamaro, T, Cox, C, Dallapiccola, B & Papa, G 1994, 'Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0)', Blood, vol. 83, no. 6, pp. 1619-1625.
Stasi R, Del Poeta G, Venditti A, Masi M, Stipa E, Dentamaro T et al. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). Blood. 1994;83(6):1619-1625.
Stasi, R. ; Del Poeta, G. ; Venditti, A. ; Masi, M. ; Stipa, E. ; Dentamaro, T. ; Cox, C. ; Dallapiccola, B. ; Papa, G. / Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). In: Blood. 1994 ; Vol. 83, No. 6. pp. 1619-1625.
@article{4aeba8e265564ab183cf28d6a81b35a7,
title = "Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0)",
abstract = "Reports of treatment of patients with minimally differentiated acute myeloid leukemia (AML-M0) are limited, heterogeneous, and controversial. We verified the prognosis of this subtype by analyzing the results of 189 consecutive patients with de novo AML. Fifteen cases fitting the criteria of AML-M0 were identified. No clinical features distinguished them from other patients with AML. The median age was 61 years (range 27 to 70), with a leukocyte count ranging from 0.6 to 185 x 109/L. In all cases the leukemic cells expressed CD34 and reacted with at least one of the antibodies to early myeloid antigens, ie, CD13, CD33, or myeloperoxidase. Immunophenotypic analysis also showed positivity for CD7 in seven samples and the multidrug- resistance P-glycoprotein (P-170) in six. Cytogenetic analysis was abnormal in 12 of the 13 patients in whom an adequate number of mitoses could be evaluated. No single abnormality prevailed, the most common findings being trisomy 8 (three cases) and aberrations of chromosome 7 (two cases). Antileukemic treatment differed according to age, but for remission induction, all patients received a combination of cytosine arabinoside and an anthracycline or mitoxantrone. The prognosis of patients with AML-M0 was remarkably poor as compared with the other French-American-British subtypes. Whereas the overall rate of complete remission (CR) was 58{\%} with a median survival of 63 weeks, only 6 of the 15 patients with AML-M0 achieved a CR, and the median survival of this group was 16 weeks (range 3 to 39). The major determinant of treatment failure was unresponsiveness to chemotherapy, as only one patient died of infection during the hypoplastic phase. The CR duration of responders was short, ranging from 3 to 22 weeks, and no second remissions were observed. We conclude that conventional combination chemotherapy yields disappointing results in AML-M0. The reason for this may be the convergence of various unfavorable prognostic factors, such as (1) the high incidence of cytogenetic abnormalities; (2) the lack of differentiation features and the expression of immaturity markers such as CD34 and CD7; and (3) the frequent expression of P-170. Nonconventional therapeutic approaches should be developed to alter the prognosis of this form of leukemia.",
author = "R. Stasi and {Del Poeta}, G. and A. Venditti and M. Masi and E. Stipa and T. Dentamaro and C. Cox and B. Dallapiccola and G. Papa",
year = "1994",
language = "English",
volume = "83",
pages = "1619--1625",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0)

AU - Stasi, R.

AU - Del Poeta, G.

AU - Venditti, A.

AU - Masi, M.

AU - Stipa, E.

AU - Dentamaro, T.

AU - Cox, C.

AU - Dallapiccola, B.

AU - Papa, G.

PY - 1994

Y1 - 1994

N2 - Reports of treatment of patients with minimally differentiated acute myeloid leukemia (AML-M0) are limited, heterogeneous, and controversial. We verified the prognosis of this subtype by analyzing the results of 189 consecutive patients with de novo AML. Fifteen cases fitting the criteria of AML-M0 were identified. No clinical features distinguished them from other patients with AML. The median age was 61 years (range 27 to 70), with a leukocyte count ranging from 0.6 to 185 x 109/L. In all cases the leukemic cells expressed CD34 and reacted with at least one of the antibodies to early myeloid antigens, ie, CD13, CD33, or myeloperoxidase. Immunophenotypic analysis also showed positivity for CD7 in seven samples and the multidrug- resistance P-glycoprotein (P-170) in six. Cytogenetic analysis was abnormal in 12 of the 13 patients in whom an adequate number of mitoses could be evaluated. No single abnormality prevailed, the most common findings being trisomy 8 (three cases) and aberrations of chromosome 7 (two cases). Antileukemic treatment differed according to age, but for remission induction, all patients received a combination of cytosine arabinoside and an anthracycline or mitoxantrone. The prognosis of patients with AML-M0 was remarkably poor as compared with the other French-American-British subtypes. Whereas the overall rate of complete remission (CR) was 58% with a median survival of 63 weeks, only 6 of the 15 patients with AML-M0 achieved a CR, and the median survival of this group was 16 weeks (range 3 to 39). The major determinant of treatment failure was unresponsiveness to chemotherapy, as only one patient died of infection during the hypoplastic phase. The CR duration of responders was short, ranging from 3 to 22 weeks, and no second remissions were observed. We conclude that conventional combination chemotherapy yields disappointing results in AML-M0. The reason for this may be the convergence of various unfavorable prognostic factors, such as (1) the high incidence of cytogenetic abnormalities; (2) the lack of differentiation features and the expression of immaturity markers such as CD34 and CD7; and (3) the frequent expression of P-170. Nonconventional therapeutic approaches should be developed to alter the prognosis of this form of leukemia.

AB - Reports of treatment of patients with minimally differentiated acute myeloid leukemia (AML-M0) are limited, heterogeneous, and controversial. We verified the prognosis of this subtype by analyzing the results of 189 consecutive patients with de novo AML. Fifteen cases fitting the criteria of AML-M0 were identified. No clinical features distinguished them from other patients with AML. The median age was 61 years (range 27 to 70), with a leukocyte count ranging from 0.6 to 185 x 109/L. In all cases the leukemic cells expressed CD34 and reacted with at least one of the antibodies to early myeloid antigens, ie, CD13, CD33, or myeloperoxidase. Immunophenotypic analysis also showed positivity for CD7 in seven samples and the multidrug- resistance P-glycoprotein (P-170) in six. Cytogenetic analysis was abnormal in 12 of the 13 patients in whom an adequate number of mitoses could be evaluated. No single abnormality prevailed, the most common findings being trisomy 8 (three cases) and aberrations of chromosome 7 (two cases). Antileukemic treatment differed according to age, but for remission induction, all patients received a combination of cytosine arabinoside and an anthracycline or mitoxantrone. The prognosis of patients with AML-M0 was remarkably poor as compared with the other French-American-British subtypes. Whereas the overall rate of complete remission (CR) was 58% with a median survival of 63 weeks, only 6 of the 15 patients with AML-M0 achieved a CR, and the median survival of this group was 16 weeks (range 3 to 39). The major determinant of treatment failure was unresponsiveness to chemotherapy, as only one patient died of infection during the hypoplastic phase. The CR duration of responders was short, ranging from 3 to 22 weeks, and no second remissions were observed. We conclude that conventional combination chemotherapy yields disappointing results in AML-M0. The reason for this may be the convergence of various unfavorable prognostic factors, such as (1) the high incidence of cytogenetic abnormalities; (2) the lack of differentiation features and the expression of immaturity markers such as CD34 and CD7; and (3) the frequent expression of P-170. Nonconventional therapeutic approaches should be developed to alter the prognosis of this form of leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0028212172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028212172&partnerID=8YFLogxK

M3 - Article

VL - 83

SP - 1619

EP - 1625

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -